UMRX Unum Therapeutics Inc.
1,886
$2.50
$0.03
(1.19%)
| Watchers | 1,886 |
| 52-Wk Low | $0.295 |
| 52-Wk High | $3.72 |
| Market Cap | $105.32M |
| Volume (M) | 6,068.00 |
| 52-Wk High | $3.72 |
| 52-Wk Low | $0.295 |
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare ConferenceGlobe Newswire • over 1 year ago
---
- 'CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences,
Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies
for genetically defined diseases, today announced Andrew Robbins, Chief Executive
Officer and President, will participate ...'
Share to Feed
---
- Cogent Biosciences, Inc. (NASDAQ:UMRX) shares reached a new 52-week high on Monday
. The company traded as high as $12.24 and last traded at $12.10, with a volume
of 201381 shares trading hands. The stock had previously closed at $11.91. UMRX
has been the topic of a number of research analyst ...
---
- Cogent Biosciences (NASDAQ:UMRX) will be releasing its earnings data before the
market opens on Thursday, November 12th. Analysts expect Cogent Biosciences to post
earnings of ($0.56) per share for the quarter. Cogent Biosciences (NASDAQ:UMRX)
last posted its quarterly earnings data on Tuesday, ...
---
- Cogent Biosciences (NASDAQ:UMRX) and Rezolute (OTCMKTS:RZLTD) are both small-cap
medical companies, but which is the better business? We will compare the two companies
based on the strength of their risk, institutional ownership, valuation, dividends,
analyst recommendations, profitability and ...
---
- Vectura Group (OTCMKTS:VEGPF) and Cogent Biosciences (NASDAQ:UMRX) are both small-cap
medical companies, but which is the superior stock? We will contrast the two companies
based on the strength of their valuation, profitability, risk, earnings, institutional
ownership, analyst recommendations and ...
---
- The fool doth think he is wise, but the wise man knows himself to be a fool." -
William Shakespeare, As You Like It Today, we take our first look at a very volatile
Busted IPO. Recent events and some beneficial owner purchases put this small cap
on our radar for further research.
---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 100,000
shares of the companys stock in a transaction dated Friday, May 8th. The stock was
sold at an average price of $0.46, for a total transaction of $46,000.00. The sale
was disclosed in a legal filing with the ...
---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 100,000
shares of the businesss stock in a transaction dated Monday, May 11th. The shares
were sold at an average price of $0.45, for a total value of $45,000.00. The sale
was disclosed in a filing with the Securities &#...
---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 98,973
shares of the companys stock in a transaction on Tuesday, April 14th. The stock
was sold at an average price of $0.40, for a total value of $39,589.20. The transaction
was disclosed in a filing with the SEC, which...
---
- Unum Therapeutics Inc (NASDAQ:UMRX) major shareholder Dario Campana sold 242,579
shares of Unum Therapeutics stock in a transaction on Monday, April 27th. The stock
was sold at an average price of $0.40, for a total value of $97,031.60. The transaction
was disclosed in a legal filing with the SEC, ...
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Latest UMRX News
Cogent Biosciences to Present at 11th Annual SVB Leerink Global Healthcare Conference
Globe Newswire • over 1 year ago
Cogent Biosciences (NASDAQ:UMRX) Hits New 52-Week High at $12.24
Ticker Report • over 2 years ago
Cogent Biosciences (UMRX) Scheduled to Post Earnings on Thursday
Ticker Report • almost 3 years ago